Mirum significantly improved its operating performance with substantially reduced losses while maintaining strong balance sheet growth across key metrics.
The company's operating losses narrowed meaningfully year-over-year, suggesting improved operational efficiency or revenue growth in their rare disease therapeutics portfolio. The concurrent growth in accounts receivable and current assets indicates expanding commercial activity, likely driven by increased sales of their three approved medicines including LIVMARLI.
Mirum demonstrated strong financial progress with operating losses and net losses both narrowing substantially while SG&A expenses grew modestly by 27%. The balance sheet strengthened across multiple dimensions, with current assets expanding 40%, cash increasing by one-third to $297M, and stockholders' equity growing 40% to $315M. The 58% increase in accounts receivable alongside higher current liabilities suggests accelerating commercial momentum, positioning the company well for continued growth in the rare disease market.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Net income grew 73.4% — bottom-line growth signals improving overall business health.
Current liabilities surged 62.6% — significant near-term obligations; verify ability to meet short-term debt.
Receivables surged 57.5% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Current assets grew 39.9% — improving short-term liquidity or inventory/receivables build.
Equity base grew 39.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Cash position surged 33.3% — strong cash generation or capital raise providing significant financial cushion.
SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.
Asset base grew 25.7% — expansion through organic growth, acquisitions, or capital deployment.
Liabilities increased 18.6% — monitor debt-to-equity ratio and interest coverage.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →